U.S. Senator Sanders will oppose Biden nominee for FDA commissioner
Reuters
Published Dec 14, 2021 04:02PM ET
Updated Dec 14, 2021 04:35PM ET
By Ahmed Aboulenein
WASHINGTON (Reuters) -U.S. Senator Bernie Sanders said on Tuesday he would oppose President Joe Biden's nominee for Food and Drug Administration Commissioner, Robert Califf, because of his ties to the pharmaceutical industry.
Biden nominated Califf, a well-regarded cardiologist and researcher closely linked with the pharmaceutical industry, in November for a second stint as commissioner. Califf previously served as FDA commissioner from February 2016 until the end of then-President Barack Obama's second term in January 2017.
"After leaving the FDA in 2017, he received consulting fees from Merck, Biogen (NASDAQ:BIIB) and Eli Lilly (NYSE:LLY)," Sanders said in a statement. "According to his financial disclosure form, he owns up to $8 million in the stocks of major drug companies. That is exactly the close relationship Big Pharma has exploited to regulate the FDA, instead of the FDA regulating them."
Sanders, an independent from Vermont, added: "I will oppose his nomination."
Sanders made the comments after a hearing of the Senate Health, Education, Labor and Pensions (HELP) committee of which he is a member. The committee will vote on whether to confirm Califf before he is considered by the full Senate. It has not scheduled a vote yet.
Senators Joe Manchin and Richard Blumenthal, both Democrats, have said previously they would oppose the nomination. Democrats have a razor-thin majority in the Senate and so Califf will need Republican support.
Califf was confirmed for his first term by the Senate 89-4 with broad bipartisan support. The HELP Committee's ranking Republican senator, Richard Burr, said after Tuesday's hearing that he will support Califf.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.